CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Gain (Loss) on Extinguishment of Debt
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Gain (Loss) on Extinguishment of Debt of -$3.97 million for the 12-month period ending 2023-12-30, per its 10-K filed 2024-02-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2024-02-14
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. gain (loss) on extinguishment of debt for the quarter ending 2023-12-30 was -$992.00K.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. gain (loss) on extinguishment of debt for the quarter ending 2023-09-30 was -$2.98M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. gain (loss) on extinguishment of debt for the quarter ending 2022-12-31 was -$1.06M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. gain (loss) on extinguishment of debt for the quarter ending 2022-09-24 was -$1.07M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. gain (loss) on extinguishment of debt for fiscal 2023 was -$3.97M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. gain (loss) on extinguishment of debt for fiscal 2022 was -$4.12M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. gain (loss) on extinguishment of debt for fiscal 2021 was -$29.96M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. gain (loss) on extinguishment of debt for fiscal 2020 was -$3.66M.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|
| 2023-12-30 | -$992.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | -$3.97M derived: sum of 2 quarters · filed 2024-02-14 | -$3.97M 10-K · filed 2024-02-14 | |
| 2023-09-30 | -$2.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$2.98M 10-Q · filed 2023-11-08 | ||
| 2023-07-01 | $0.00 10-Q · filed 2023-08-09 | |||
| 2022-12-31 | -$1.06M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | -$2.13M derived: sum of 2 quarters · filed 2024-02-14 | -$3.09M derived: sum of 3 quarters · filed 2024-02-14 | -$4.12M 10-K · filed 2024-02-14 |
| 2022-09-24 | -$1.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$2.03M derived: sum of 2 quarters · filed 2023-11-08 | -$3.05M 10-Q · filed 2023-11-08 | -$4.05M derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-06-25 | -$959.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$1.99M 10-Q · filed 2023-08-09 | -$2.98M derived: sum of 3 quarters · filed 2024-02-14 | -$3.97M derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-03-26 | -$1.03M 10-Q · filed 2022-05-04 | -$2.02M derived: sum of 2 quarters · filed 2024-02-14 | -$3.01M derived: sum of 3 quarters · filed 2024-02-14 | -$4.08M derived: sum of 4 quarters · filed 2024-02-14 |
| 2021-12-25 | -$992.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | -$1.98M derived: sum of 2 quarters · filed 2024-02-14 | -$3.06M derived: sum of 3 quarters · filed 2024-02-14 | -$29.96M 10-K · filed 2024-02-14 |
| 2021-09-25 | -$992.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | -$2.06M derived: sum of 2 quarters · filed 2022-11-02 | -$28.97M 10-Q · filed 2022-11-02 | -$29.87M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-26 | -$1.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$27.98M 10-Q · filed 2022-08-03 | -$28.88M derived: sum of 3 quarters · filed 2023-02-22 | -$31.64M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-27 | -$26.91M 10-Q · filed 2022-05-04 | -$27.81M derived: sum of 2 quarters · filed 2023-02-22 | -$30.57M derived: sum of 3 quarters · filed 2023-02-22 | -$30.57M derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-26 | -$902.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | -$3.66M derived: sum of 2 quarters · filed 2023-02-22 | -$3.66M derived: sum of 3 quarters · filed 2023-02-22 | -$3.66M 10-K · filed 2023-02-22 |
| 2020-09-26 | -$2.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$2.76M derived: sum of 2 quarters · filed 2021-11-03 | -$2.76M 10-Q · filed 2021-11-03 | |
| 2020-06-27 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $0.00 10-Q · filed 2021-08-04 | ||
| 2020-03-28 | $0.00 10-Q · filed 2021-05-04 | |||
| 2019-12-28 | -$4.94M 10-K · filed 2022-02-16 | |||
| 2013-09-28 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-30 | $389.00K 10-Q · filed 2013-10-30 | ||
| 2013-06-29 | $389.00K 10-Q · filed 2013-07-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |